Affymetrix Inks $70 Million Deal with Roche, Hits Its Fourth Quarter Financial Marks | GenomeWeb

Affymetrix, the bell cow of the emerging microarray industry, last week trotted out a sparkling fourth-quarter earnings report and then, less than 24 hours later, announced a $70 million, 18-year technology licensing deal with Roche. And, Wall Street responded enthusiastically.

Financially, Affymetrix put together a second consecutive quarter of profitability and narrowed losses on the year. And, the company set out positive guidance, whetting market expectations for 2003.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The BabySeq project faces lower-than-expected enrollment rates, according to ScienceInsider.

In Nature this week: modern European bison analysis, phased diploid genome assembly algorithms, and more.

Actress Jennifer Lopez is working with NBC on a CRISPR-inspired television show, according to the Hollywood Reporter.

Researchers trace the origin of one human papillomavirus lineage to Neanderthals or Denisovans, Vox reports.